Systematic review and meta-analysis of tumour microsatellite-instability status as a predictor of response to fluorouracil-based adjuvant chemotherapy in colorectal cancer

• Published in: International journal of colorectal disease 2022-01, Vol.37 (1), p.35-46
• Main Authors: Aggarwal, Nikhil, Quaglia, Alberto, McPhail, Mark J. W., Monahan, Kevin J.
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; Adjuvant treatment; Analysis; Cancer; Care and treatment; Chemotherapy; Chemotherapy, Adjuvant; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Fluorouracil; Fluorouracil - therapeutic use; Gastroenterology; Hepatology; Humans; Internal Medicine; Literature reviews; Medicine; Medicine & Public Health; Meta-analysis; Microsatellite Instability; Microsatellite Repeats - genetics; Oncology, Experimental; Patients; Proctology; Prognosis; Review; Statistical analysis; Surgery; Survival; Tumors
• ISSN: 0179-1958; 1432-1262
• DOI: 10.1007/s00384-021-04046-x

Purpose Colorectal cancer (CRC) can be classified according to the chromosomal-instability pathway (a microsatellite-stable (MSS) pathway) and the microsatellite-instability (MSI) pathway. Adjuvant therapy after surgery in advanced CRC is usually based on fluoropyrimidine 5-fluorouracil (5-FU) alone or combined with other agents. Controversy however remains on the use of 5-FU-based regimens in treating MSI-related tumours. Aims To systematically investigate the relationship between tumour microsatellite profile and 5-year overall survival in patients with CRC treated with 5-FU. Methods A systematic literature review of PubMed and Embase databases was conducted. Pre-specified criteria determined study inclusion/exclusion. The PRISMA and QUADAS-2 criteria were used to assess study suitability and quality respectively. Patients were categorised as having either MSI or MSS CRC. Overall 5-year survival was estimated from Kaplan–Meier curves. Publication bias was assessed using funnel-plots and Egger’s test. Results 1807 studies were identified, with meta-analysis performed using nine studies. 5-FU treated individuals with CRC who died at 5 years were found to be 0.31 times less likely to have MSI than those who were alive, although this was not statistically significant. There was an insufficient number of studies to enable subgroup analysis by stage. Conclusions In this meta-analysis, MSI status does not alter 5-year survival of patients with CRC patients treated with adjuvant 5-FU, however there is significant heterogeneity in the design of individual studies in the data synthesis. More studies are necessary to clarify whether CRC patients with MSI CRC, in particular early stage, should be offered 5-FU based adjuvant chemotherapy.